دورية أكاديمية
Sex-specific disparities in disease activity scores among patients with axial spondyloarthritis and their implications for evaluating the response to tumor necrosis factor alpha inhibitor therapy
| العنوان: | Sex-specific disparities in disease activity scores among patients with axial spondyloarthritis and their implications for evaluating the response to tumor necrosis factor alpha inhibitor therapy |
|---|---|
| المؤلفون: | Seulkee Lee, Seonyoung Kang, Hyungjin Kim, Jaejoon Lee, Min-Ji Kim, Hoon-Suk Cha |
| المصدر: | Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-9 (2024) |
| بيانات النشر: | BMC, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Diseases of the musculoskeletal system |
| مصطلحات موضوعية: | Axial spondyloarthritis, Patient reporting outcome, Sex, TNF alpha inhibitor, Disease activity, Diseases of the musculoskeletal system, RC925-935 |
| الوصف: | Abstract Background We aimed to investigate whether there are sex differences in disease activity measures among patients with axial spondyloarthritis (axSpA) and to determine any potential impact on the assessment of treatment responses to tumor necrosis factor alpha inhibitors (TNFi). Methods Using the Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry data, we compared sex differences in changes in the Bath Ankylosing Spondylitis Disease Activity Score (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) levels at baseline and one year after TNFi initiation in patients with axSpA. Results This study included 1,753 patients with axSpA who started or changed TNFi, of whom 1,343 (76.6%) were male. At baseline, the mean BASDAI and ASDAS scores of all patients were 5.98 and 3.6, respectively. The BASDAI changes between baseline and the one-year follow-up were independently associated with sex (𝛽 = 0.343, p = 0.011), whereas ASDAS was not (𝛽 = 0.079, p = 0.235). When judging the effect of TNFi at one-year of treatment, male patients were more likely to be assessed as effective by the BASDAI-based criterion (ΔBASDAI ≥ 50% or ≥ 2; OR 1.700, 95% CI 1.200–2.406), while the ASDAS-based criterion (ΔASDAS ≥ 1.1) showed no significant difference between sexes (OR 0.993, 95% CI 0.678–1.455), after adjusting for other baseline characteristics. Conclusions The changes in disease activity before and after TNFi use were significantly different between sexes when measured by BASDAI, but not ASDAS. TNFi treatment effects may be interpreted differently between sexes depending on the disease activity measure used. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1478-6362 48040789 |
| Relation: | https://doaj.org/toc/1478-6362 |
| DOI: | 10.1186/s13075-024-03320-x |
| URL الوصول: | https://doaj.org/article/f804f213c480407896ff322bb7b2700a |
| رقم الأكسشن: | edsdoj.f804f213c480407896ff322bb7b2700a |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 14786362 48040789 |
|---|---|
| DOI: | 10.1186/s13075-024-03320-x |